Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Options Box -- Ignore unavailable to you. Want to Upgrade?

To: Poet who wrote (9866)	3/6/2001 9:26:34 AM
From: hobo	Respond to of 10876

Good morning Po, EDIT : correcting some comments: I found this Company, sounds interesting and looking at the chart VVUS seems to be rebounding from the low 30's at the end of 1997. I found it on an scan on TC 2000 and I also found these news: I could not find an option chain on it though... (This toys are amazing !!) MOUNTAIN VIEW, Calif., Mar 6, 2001 (BW HealthWire) VIVUS Inc. (Nasdaq:VVUS), a pharmaceutical company developing innovative products to improve quality of life, today announced that the company will hold a conference call to discuss its licensing agreement with TANABE SEIYAKU, a leading Japanese pharmaceutical company, for TANABE's proprietary phosphodiesterase inhibitor type 5 (PDE5) compound TA1790 for the oral and local treatment of male and female sexual dysfunction. The conference call will be held today, Tuesday, March 6, 2001, at 1:00 p.m. EST. Investors can listen to this call (live or 90day replay) via the Internet at the company's Web site: www.vivus.com. To listen to the live call, go to the Web site a few minutes prior to the start of the call to register, download and install the necessary audio software. TA1790 is a fast acting, highly selective, potent PDE5 inhibitor. PDE5 inhibitors, such as Pfizer's (NYSE:PFE) Viagra(R), have been shown to be effective oral treatments for male erectile dysfunction (ED) and are being studied as potential therapies for female sexual dysfunction (FSD). "We are holding this conference call so that our investors can understand the strategic implications of this important agreement," commented Leland F. Wilson, president and chief executive officer of VIVUS Inc. VIVUS Inc. is a pharmaceutical company developing innovative products to improve quality of life disorders in men and women, with a focus on sexual dysfunction. The company developed and markets in the U.S. MUSE (alprostadil) and ACTIS(R) (recently cleared for OTC marketing), two innovations in the treatment of erectile dysfunction, and has partnered with Abbott Laboratories (NYSE:ABT) for the international marketing and distribution of its male transurethral ED products. In Canada, VIVUS is partnered exclusively with Paladin Labs to market and distribute MUSE. VIVUS initiated clinical studies for its female sexual dysfunction product, ALISTA, during the fourth quarter of 2000. TANABE SEIYAKU Co. Ltd. is a leading Japanese pharmaceutical company that specializes in developing and marketing pharmaceutical products such as diltiazem (Herbesser(R)) and imidapril (Tanatril(R)) to treat cardiovascular diseases. Currently, diltiazem is sold in more than 120 countries and imidapril is sold in Asia and European countries. The company is dedicated to the discovery, research and development of pharmaceutical products that meet emerging medical needs. For more information, visit the Web site at www.tanabe.co.jp. This news release contains forwardlooking statements that involve risks and uncertainties regarding VIVUS Inc.'s operations and future results. See the company's filings with the Securities and Exchange Commission including, without limitation, the company's Form 10K and Form 10Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forwardlooking statements. Note to editors and investors: Additional written materials, recent releases and company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS FaxOnDemand Service (888/3295719). CONTACT: VIVUS Inc. Richard Walliser, 650/9345200 ir@vivus.com www.vivus.com or Lippert/Heilshorn & Associates Inc. Bruce Voss/Bonnie Feldman, 310/6917100 (Investors) bvoss@lhai.com bfeldman@lhai.com Pamela Rigler, 212/8383777 (Media) prigler@lhai.com www.lhai.com URL: businesswire.com Today's News On The Net Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2001 Business Wire. All rights reserved.

To: Poet who wrote (9866)	3/6/2001 6:26:51 PM
From: mishedlo	Read Replies (2) \| Respond to of 10876

Poet how do you handle these ramps. I got caught in AMAT and MU both. Since they are Apr I just rode it out. Still holding IBM that Toscano chasticed me about. Fortunately I had some calls today to sell that I bought as protection. SSTI and CREE. Got rid of both near the highs. This is one hell of a market to try and trade. Stll ahead on KSS but let huge profits slip away. Did buy a big bunch of COLT PUTs at that ramp was totally obscene. This company is losing $1 and they ramp this POS. Glad I took profits on this one in the 63-65 area, now at 77 today. I bought in today at 76. Maybe my problem is that I think everything I should play perfect. When I do not I feel bad. Thoughts? M